Molecular Markers and Genetic Markers in Patients Undergoing Radiation Therapy for Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Rutgers, The State University of New Jersey
ClinicalTrials.gov Identifier:
NCT00899808
First received: May 9, 2009
Last updated: March 17, 2011
Last verified: March 2011
  Purpose

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is looking at molecular markers and genetic markers in patients undergoing radiation therapy for cancer.


Condition
Malignant Tumor of Lymphoid Hemopoietic and Related Tissue
Unspecified Adult Solid Tumor, Protocol Specific
Unspecified Childhood Solid Tumor, Protocol Specific

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Molecular and Genetic Markers in the Local-regional Management of Patients Undergoing Radiation Therapy

Resource links provided by NLM:


Further study details as provided by Rutgers, The State University of New Jersey:

Estimated Enrollment: 0
Study Start Date: May 2006
Primary Completion Date: May 2006 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

Primary

  • Determine local-regional control in patients undergoing radiation therapy for cancer, as a function of expression of specific molecular/genetic markers.

Secondary

  • Determine complications of radiation therapy for patients undergoing radiation therapy for cancer.

OUTLINE: Previously collected tissue samples are analyzed using immunohistochemical staining and other molecular/genetic study methods to detect markers, including p53, cyclin D1, HER-2-neu, bcl-2/BAX, and EGFR. Patient charts are also reviewed with emphasis on local-regional relapse.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

All patients undergoing radiation therapy for malignant disease will be eligible for these studies. Initially we will focus on specific disease sites, such as breast, prostate and lung, but ultimately we will expand this to include any disease site. Patients who met standard criteria for radiation therapy but ultimately did not receive radiation therapy will be used as a control arm if needed.

Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of cancer
  • Undergoing radiation therapy for malignant disease

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00899808

Locations
United States, New Jersey
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States, 08903
Sponsors and Collaborators
University of Medicine and Dentistry of New Jersey
Investigators
Principal Investigator: Bruce G. Haffty, MD Rutgers Cancer Institute of New Jersey
  More Information

Additional Information:
No publications provided

Responsible Party: Bruce Haffty, MD, Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
ClinicalTrials.gov Identifier: NCT00899808     History of Changes
Other Study ID Numbers: CDR0000592887, P30CA072720, CINJ-000609, CINJ-IRB-0220060141
Study First Received: May 9, 2009
Last Updated: March 17, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Rutgers, The State University of New Jersey:
unspecified adult solid tumor, protocol specific
unspecified childhood solid tumor, protocol specific
hematopoietic/lymphoid cancer

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on August 01, 2014